Treatment of Conjunctival-Corneal Intraepithelial Neoplasia with Topical Mitomycin C.
- Author:
Hyun Jun PARK
1
;
Ji Eun LEE
;
Jong Soo LEE
;
Do Yoon PARK
Author Information
1. Department of Ophthalmology, Pusan National University College of Medicine, Pusan, Korea. jongsool@pusan.ac.kr
- Publication Type:Case Report
- Keywords:
Conjunctival-corneal intraepithelial neoplasia (CCIN);
Topical mitomycin C
- MeSH:
Follow-Up Studies;
Humans;
Keratitis;
Mitomycin*;
Recurrence;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2003;44(8):1924-1930
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the therapeutic effect of topical mitomycin C (MMC) on the diffuse conjunctival-corneal intraepithelial neoplasia (CCIN). METHODS: Three patients histopathologically confirmed the conjunctival-corneal intraepithelial neoplasia (CCIN) received topical drop of 0.04% MMC four times daily for 2 to 4 weeks. Ocular complications and recurrence were evaluated under slit lamp biomicroscope. RESULTS: One case received topical drop of 0.04% MMC four times daily for 2 weeks and two cases of CCIN received for 4 weeks in the same manner. These lesions were completely regressed and did not recur under slit lamp biomicroscope during the follow-up of 18 months, 6 months, and 5 months, respectively. Other complications except superficial punctate keratitis and conjunctival injection did not develope and visual acuities have been improved. CONCLUSIONS: It appears that the application of topical MMC alone could be a primary effective treatment for diffuse conjunctival-corneal intraepithelial neoplasia (CCIN).
